AssetMark Inc
TXG icon

AssetMark Inc’s 10x Genomics TXG Stock Holding History

AssetMark Inc’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18
Closed -$1K – 1662
2022
Q3 		$1K Buy
+18
New +$686 ﹤0.01% 1488
2022
Q1 		– Sell
-1,121
Closed -$167K – 1747
2021
Q4 		$167K Buy
1,121
+1,010
+910% +$155K ﹤0.01% 732
2021
Q3 		$16K Buy
+111
New +$19.1K ﹤0.01% 983

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AssetMark Inc's TXG Position: Q4 2022 in Review

AssetMark Inc sold out of 10x Genomics (TXG) in Q4 2022, closing a stake of 18 shares — an estimated $1K sold.

AssetMark Inc first reported a position in TXG in Q3 2021 and held it in 3 quarters. The position peaked at $167K in Q4 2021. 268 funds tracked by Wall St. Rank hold TXG as of Q4 2022.

  • AssetMark Inc reported no remaining 10x Genomics position as of Q4 2022 after selling out during the quarter.
  • AssetMark Inc sold 18 10x Genomics shares in Q4 2022, an estimated $1K.
  • AssetMark Inc first reported a position in 10x Genomics in Q3 2021 and held it in 3 quarters.
  • AssetMark Inc's 10x Genomics position peaked at $167K in Q4 2021.
  • 268 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2022.

Based on AssetMark Inc's 13F filing for Q4 2022, filed 10 Feb 2023.